Amgen (NASDAQ:AMGN) Price Target Raised to $410.00 at Daiwa Securities Group

Amgen (NASDAQ:AMGN) had its price target boosted by Daiwa Securities Group from $370.00 to $410.00 in a report released on Tuesday,MarketScreener reports. The brokerage presently has an “outperform” rating on the medical research company’s stock. Daiwa Securities Group’s price target suggests a potential upside of 10.06% from the company’s previous close.

AMGN has been the topic of several other reports. Royal Bank Of Canada lifted their target price on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th. Scotiabank started coverage on Amgen in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price objective for the company. The Goldman Sachs Group raised their target price on shares of Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Argus upped their price target on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday. Finally, TD Cowen reissued a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Amgen presently has an average rating of “Moderate Buy” and an average price target of $353.39.

Amgen Trading Down 0.9%

Amgen stock opened at $372.54 on Tuesday. The business has a 50-day simple moving average of $335.21 and a two-hundred day simple moving average of $311.98. Amgen has a 52-week low of $261.43 and a 52-week high of $385.12. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The company has a market cap of $200.60 billion, a P/E ratio of 26.16, a P/E/G ratio of 3.96 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same period in the previous year, the business posted $5.31 earnings per share. The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts predict that Amgen will post 20.62 EPS for the current year.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 10,908 shares of company stock worth $3,674,966. Company insiders own 0.69% of the company’s stock.

Institutional Trading of Amgen

A number of hedge funds have recently bought and sold shares of AMGN. Laurel Wealth Advisors LLC raised its position in shares of Amgen by 27,765.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after purchasing an additional 6,676,575 shares during the last quarter. Norges Bank acquired a new position in Amgen during the 2nd quarter valued at approximately $1,663,726,000. Capital World Investors raised its holdings in shares of Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after buying an additional 1,935,876 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after buying an additional 1,035,779 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after buying an additional 961,975 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.